View this post on Instagram
Claim: “Donald Trump Has Stake In Hydroxychloroquine Drugmaker: Report” That’s the headline across a HuffPost story that goes on to claim that “President Donald Trump reportedly owns a stake in a company that produces hydroxychloroquine, the anti-malaria drug he has repeatedly touted as a coronavirus treatment even though his experts say there’s no strong evidence it works.” Verdict: False. The report cited by the HuffPost is from a New York Times story that said: “Trump himself has a small personal financial interest in Sanofi, the French drugmaker that makes Plaquenil, the brand-name version of hydroxychloroquine.” Trump’s personal financial interest, however, does not include a stake in Sanofi–and the New York Times did not claim it did. Instead, Trump’s financial disclosures show that his three family trusts each had investments in a $10.3 billion Dodge & Cox mutual fund that owns shares in Sanofi, the world’s fifth-largest drugmaker by prescription sales. As of its latest disclosures, those holdings amount to just 3.3 percent of the fund’s holdings. Trump’s most recent financial disclosure forms lists holdings in the Dodge & Cox International Fund valued between $1,001 and $15,000. That means Trump holds a maximum stake in the mutual funds of $35,000, giving him an indirect interest in Sanofi of $1,155 at the most. His “financial interest” in Sanofi, which has a market capitalization of nearly $58 billion, could be as low as $99.10.
Let’s get real: @realDonaldTrump has plenty of political and psychological reasons to want to push hydroxychloroquine without being motivated by $99 or even $9,900.@QuinHillyer says trafficking in anti-Trump speculation of this sort is unhealthy.— Washington Examiner (@dcexaminer) April 7, 2020